View Older Stories View More Recent Stories
-
Form 8-K MDB Capital Holdings, For: Jul 31
-
Form 424B4 MDB Capital Holdings,
-
Form EFFECT MDB Capital Holdings,
-
Form 8-A12B MDB Capital Holdings,
-
Form S-1/A MDB Capital Holdings,
-
Form S-1/A MDB Capital Holdings,
-
Paris finance summit to push development banks to take on more risk -draft
-
Form S-1/A MDB Capital Holdings,
-
Form S-1/A MDB Capital Holdings,
-
Form S-1/A MDB Capital Holdings,
-
Global Hemp Group Announces Execution of Binding LOI with Apollon Formularies PLC
-
Form S-1/A MDB Capital Holdings,
-
MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval
-
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
-
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
-
MDB Capital Holdings Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
-
MDB Capital Holdings (MDBH) Announces 833K Share IPO at $12/sh
-
Form S-1 MDB Capital Holdings,
-
Form D MDB Capital Holdings,
-
Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application
-
Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors
-
Clearsign Combustion (CLIR) and Anthony DiGiandomenico Reach Pact to Refresh ClearSign's Board
-
ClearSign and Anthony DiGiandomenico Reach Agreement to Refresh ClearSign's Board and Ensure Smooth Management Transition
-
Sorrento Therapeutics (SRNE) Subsidiary Scilex Announces $140M in Non-Dilutive Royalty-Based Financing for Commercialization of Non-Opioid ZTlido Pain Medication
-
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
-
Form SC 13D/A Provention Bio, Inc. Filed by: MDB CAPITAL GROUP LLC
-
Form SC 13D/A Provention Bio, Inc. Filed by: MDB CAPITAL GROUP LLC
-
Form 4 Provention Bio, Inc. For: Jul 19 Filed by: MDB CAPITAL GROUP LLC
-
Provention Bio Announces Closing of Upsized Initial Public Offering
-
Form SC 13D Provention Bio, Inc. Filed by: MDB CAPITAL GROUP LLC
-
Form 3 Provention Bio, Inc. For: Jul 03 Filed by: MDB CAPITAL GROUP LLC
-
Mox Reports long Pulse Biosciences, Inc. (PLSE)
-
Cue Biopharma Announces Closing of Initial Public Offering
-
Securities Litigation Partner Robert Weber Joins Sheppard Mullin Century City
-
Provention Bio, Inc. Announces Clinical Program Focused on Intercepting and Preventing the Onset of Type 1 Diabetes
-
Provention Bio, Inc. Secures $28.4 Million Founding Financing to Fund Development Targeting the Interception and Prevention of Immune-Mediated Disease
-
Pulse Biosciences, Inc. (PLSE) Lower as TheStreetSweeper Out Negative, Sees 92% Downside
-
Aqua Metals (AQMS) Ticks Lower Following Cautious Mention on SA
-
Media Startup TheMaven Network Inc. Completes Private Placement Raising $3.7 Million
-
ClearSign Combustion Corporation Closes Rights Offering for Gross Proceeds of $9.6 Million
-
ClearSign Combustion Corporation Updates Information on Rights Offering
-
Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to Selectively Control T Cell Activity
-
ClearSign Combustion Corporation Announces Rights Offering
-
Clean Diesel Technologies (CDTI) Enters $10.3M Private Placement Equity Raise
-
CDTi Announces Signing of Securities Purchase Agreement to Raise Approximately $10.3 Million
-
New Digital Media Network, "theMaven," Announced by James Heckman and Former Scout Executive Team; Sign Acquisition Agreement to Become a Public Company
-
TheStreetSweeper Cautious on Energous (WATT)
-
Global Intellectual Property Firm Murgitroyd Expands Strategic & Search Capabilities
-
Pulse Biosciences Announces Closing of Initial Public Offering Over-allotment
-
Pulse Biosciences Announces Closing of Initial Public Offering

